|
|
Argenx se
ARGX's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Looking into Argenx Se growth rates, revenue grew
by 191.46 % in IV. Quarter 2023 from the same quarter a year ago.
Ranking at No. 126
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -3.71 %
Argenx Se net loss decreased from $-710 millions, to $-295 millions in IV. Quarter 2023,
• More on ARGX's Growth
|
|
Argenx Se
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 38.81 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 12.46.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.91.
• More on ARGX's Valuation
|
|
|
|
|
Argenx Se
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 38.81 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 12.46.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.91.
Argenx Se Price to Book Ratio is at 7.58 lower than Industry Avg. of 1050.72. and higher than S&P 500 Avg. of 0
• More on ARGX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
